retatrutide clinical trials safety efficacy and of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled Lilly orforglipron oral GLP-1 phase

The extra lipid in the liver comes from several different ways

First, let me caution that this is just a mouse study, so it may not hold true in humans

We report that in pre-clinical models with significant retatrutide (RETA, LY3437943)-induced weight loss, pancreatic cancer engraftment was reduced, tumor onset was delayed, and progression was attenuated resulting in a 14-fold reduction in tumor volume compared to only 4-fold reduction in single agonist semaglutide-treated mice

Glucagon: This is the novel component

At 24 weeks, retatrutide 12 mg delivers 17.5% body weight loss versus an estimated 12-13% for tirzepatide 15 mg

The STEP trial extension data showed that participants regained approximately 40 percent of lost weight within 28 weeks of stopping semaglutide